Clinical Trial

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Investigator
Complete title:
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors
Trial phase:
Phase II
Study ID:
NCT03645928
Local study ID:
RG1003670
Summary:
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with pembrolizumab or TIL LN-145/LN-145-S1 as a single therapy.
Trial keywords:
Lung Carcinoma, Non-Small-Cell (NSCLC), Neoplasms, Squamous Cell, Neoplasm Metastasis
Enrollment status:
Recruiting
Trial eligibility
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Learn more

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Contact us

For more information about SCCA and to schedule an appointment.